Compare Stocks → The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AIMTNASDAQ:APLSNASDAQ:EIDXNASDAQ:INSMNASDAQ:TCDA Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIMTAimmune Therapeutics$34.49$34.46$10.09▼$37.00$2.26B1.761.71 million shsN/AAPLSApellis Pharmaceuticals$48.03-7.3%$60.54$19.83▼$94.75$5.79B0.881.50 million shs1.68 million shsEIDXEidos Therapeutics$122.21$123.21$28.39▼$132.54$4.75B-0.16128,113 shsN/AINSMInsmed$26.18+0.1%$27.58$17.35▼$32.00$3.89B0.921.68 million shs1.21 million shsTCDATricida$0.13$0.09▼$13.85$6.01M0.2217.62 million shs31.13 million shsBeginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIMTAimmune Therapeutics0.00%0.00%0.00%0.00%0.00%APLSApellis Pharmaceuticals-7.31%-15.50%-14.63%-24.81%-41.53%EIDXEidos Therapeutics0.00%0.00%0.00%0.00%0.00%INSMInsmed+0.11%-7.78%+0.15%-7.95%+48.50%TCDATricida0.00%0.00%0.00%0.00%0.00%The “Perfect Storm” for Gold (Ad)Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.Click here now to download the free Precious Metals Buying Guide!MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAIMTAimmune TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAPLSApellis Pharmaceuticals4.3829 of 5 stars4.42.00.04.41.92.50.6EIDXEidos TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AINSMInsmed4.0397 of 5 stars4.51.00.04.53.10.00.6TCDATricidaN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAIMTAimmune TherapeuticsN/AN/AN/AN/AAPLSApellis Pharmaceuticals2.87Moderate Buy$77.9362.26% UpsideEIDXEidos TherapeuticsN/AN/AN/AN/AINSMInsmed3.00Buy$44.6470.50% UpsideTCDATricidaN/AN/AN/AN/ACurrent Analyst RatingsLatest EIDX, AIMT, INSM, APLS, and TCDA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/17/2024APLSApellis PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$67.00 ➝ $57.004/15/2024APLSApellis PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$92.004/11/2024INSMInsmedBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$37.00 ➝ $40.004/9/2024APLSApellis PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$85.004/1/2024INSMInsmedWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$55.003/27/2024APLSApellis PharmaceuticalsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$60.003/6/2024APLSApellis PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$78.00 ➝ $79.003/4/2024APLSApellis PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$87.00 ➝ $89.002/28/2024APLSApellis PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$92.002/28/2024APLSApellis PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$60.00 ➝ $67.002/27/2024INSMInsmedGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$52.00 ➝ $54.00(Data available from 4/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAIMTAimmune TherapeuticsN/AN/AN/AN/A$1.66 per shareN/AAPLSApellis Pharmaceuticals$396.59M14.60N/AN/A$1.64 per share29.29EIDXEidos Therapeutics$26.69M177.99N/AN/A$4.57 per share26.74INSMInsmed$305.21M12.74N/AN/A($2.32) per share-11.28TCDATricidaN/AN/AN/AN/AN/AN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAIMTAimmune Therapeutics-$248.50M-$3.97N/AN/AN/AN/A-164.99%-89.50%N/AAPLSApellis Pharmaceuticals-$528.63M-$4.48N/A44.47N/A-133.34%-178.60%-60.41%5/2/2024 (Estimated)EIDXEidos Therapeutics-$37.83M-$1.03N/AN/AN/AN/A-65.21%-53.04%N/AINSMInsmed-$749.57M-$5.34N/AN/AN/A-245.59%N/A-53.34%5/2/2024 (Estimated)TCDATricida-$176.57M-$2.36N/AN/AN/AN/AN/A-103.81%N/ALatest EIDX, AIMT, INSM, APLS, and TCDA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/27/202412/31/2023APLSApellis Pharmaceuticals-$0.73-$0.73N/A-$0.73$143.34 million$146.38 million 2/22/202412/31/2023INSMInsmed-$1.13-$1.28-$0.15-$1.28$82.15 million$83.70 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAIMTAimmune TherapeuticsN/AN/AN/AN/AN/AAPLSApellis PharmaceuticalsN/AN/AN/AN/AN/AEIDXEidos TherapeuticsN/AN/AN/AN/AN/AINSMInsmedN/AN/AN/AN/AN/ATCDATricidaN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAIMTAimmune Therapeutics0.737.537.40APLSApellis Pharmaceuticals0.483.102.50EIDXEidos Therapeutics0.1411.1011.10INSMInsmedN/A4.123.75TCDATricidaN/A4.874.87OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAIMTAimmune Therapeutics74.47%APLSApellis Pharmaceuticals96.29%EIDXEidos Therapeutics31.40%INSMInsmedN/ATCDATricidaN/AInsider OwnershipCompanyInsider OwnershipAIMTAimmune Therapeutics13.75%APLSApellis Pharmaceuticals7.50%EIDXEidos Therapeutics70.10%INSMInsmed4.60%TCDATricida35.60%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAIMTAimmune Therapeutics22865.45 millionN/AOptionableAPLSApellis Pharmaceuticals702120.58 million111.54 millionOptionableEIDXEidos Therapeutics7038.87 millionN/ANot OptionableINSMInsmed373148.55 million141.72 millionOptionableTCDATricida5755.67 million35.85 millionNot OptionableEIDX, AIMT, INSM, APLS, and TCDA HeadlinesSourceHeadlineSierraConstellation Partners Receives Industry Recognition for Work with Tricidafinance.yahoo.com - February 6 at 10:02 AMTricida Inc (TCDAQ)es.investing.com - January 13 at 10:29 AMEmerging Therapies in the Treatment of Clostridium difficile-Associated Diseasemedscape.com - May 30 at 8:27 AMVaniam Group Hires Paula Franson to Lead Clinical Strategy & Solutions - Yahoo Financenews.google.com - April 18 at 12:45 AMMetabolic Acidosis Market to Witness Growth by 2032, Estimates ... - Digital Journalnews.google.com - April 17 at 7:44 PMReal-time PCR as a Diagnostic Tool for Bacterial Diseasesmedscape.com - April 12 at 11:47 PMChronic Kidney Disease Drugs Market Expected To Propel Market ... - Digital Journalnews.google.com - April 10 at 8:38 AMChronic Kidney Disease Drugs Market Huge Growth in Future ... - Digital Journalnews.google.com - April 6 at 7:54 AMTricida Heading For Ch. 11 Confirmation Fight With Creditors - Law360news.google.com - March 24 at 11:19 PMAlicia Dixon Joins COPILOT Provider Support Services as VP of Strategy Development & Execution - Yahoo Financenews.google.com - March 14 at 3:50 PMAlicia Dixon Joins COPILOT Provider Support Services as VP of ... - Yahoo Financenews.google.com - March 14 at 10:49 AMTricida Heads To Ch. 11 Mediation Over Creditor Plan Issues - Law360news.google.com - March 6 at 10:59 PMTroubled Adamis To Merge With Private DMK, Focus On ... - Scripnews.google.com - March 1 at 12:17 PMRelease Opt Out Trips Up Tricida Ch. 11 Disclosure Approval - Law360news.google.com - February 27 at 8:43 PMRenibus Buys Tricida's Kidney Drug Veverimer In Ch. 11 Sale - Law360news.google.com - February 21 at 8:22 PMSTONEHILL CAPITAL MANAGEMENT LLC Buys 2, Sells 3 in 4th ... - GuruFocus.comnews.google.com - February 18 at 1:53 AMTop 5 4th Quarter Trades of ORBIMED ADVISORS LLC - GuruFocus.comnews.google.com - February 18 at 1:53 AMTricida, Inc. (TCDA) Stock Historical Prices & Data - Yahoo Financefinance.yahoo.com - February 14 at 7:22 PMRising Serum Bicarbonate Lowers CKD Progression Risk in ... - Renal and Urology Newsnews.google.com - February 8 at 7:43 AMFirm Retention Summary: Tricida Inc.wsj.com - February 3 at 3:38 PMTricida's Chapter 11 Liquidation – Global Legal Chronicle - Global Legal Chroniclenews.google.com - January 29 at 8:47 AMTricida Gets OK To Seek Stalking Horse For Ch. 11 Auction - Law360news.google.com - January 26 at 6:43 PMWeak Fundamental Momentum Drags Tricida Inc. (TCDA) Lower - Marketing Sentinelnews.google.com - January 24 at 2:09 PMTricida Inc. (TCDA): This Stock is set to Soar Above its Peers - Invest Chroniclenews.google.com - January 24 at 9:08 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAimmune TherapeuticsNASDAQ:AIMTAimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy. The company also engages in the research and development of AR201, a CODIT product candidate for the treatment of egg allergy in pediatric and young adult patients; and other CODIT product candidates targeting food allergies, such as cow's milk allergy. Aimmune Therapeutics, Inc. has a strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics; and clinical collaboration agreement with Regeneron Ireland Unlimited Company and Sanofi Biotechnology SAS to study AR101 with adjunctive dupilumab in peanut-allergic patients in a Phase II trial. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. Aimmune Therapeutics, Inc. was founded in 2011 and is headquartered in Brisbane, California.Apellis PharmaceuticalsNASDAQ:APLSApellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.Eidos TherapeuticsNASDAQ:EIDXEidos Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) or amyloidosis (ATTR). It is developing AG10, which is in phase 3 clinical trial, is an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. The company was founded in 2013 and is headquartered in San Francisco, California. Eidos Therapeutics, Inc. is a subsidiary of BridgeBio Pharma, Inc.InsmedNASDAQ:INSMInsmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.TricidaNASDAQ:TCDATricida, Inc. is a pharmaceutical company. It focuses on the development and commercialization of its product, TRC101, a non-absorbed, orally-administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease. The company was founded by Gerrit Klaerner and Craig Jon Hawker on May 22, 2013 and is headquartered in South San Francisco, CA. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.